- Home
- Announcements 2022
- Complement Therapeutics General Overview
- Complement Therapeutics Disease Indications
- Pipeline
- Alzheimer's disease
- Schizophrenia
- Multiple Sclerosis-Autoimmune
- Neuromyelitis Optica-Autoimmune
- Myasthenia Gravis-Autoimmune
- Amyotrophic Lateral Sclerosis (ALS) Autoimmune
- Age-Related Macular Degeneration
- Paroxysmal Nocturnal Hemoglobinuria
- Cutaneous Squamous Cell Carcinoma (cSCC)
- Cardiac and Myocardial Ischemia
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Technology
- Staff Publications
- Funding
- Scientific Advisory Board (SAB)
- Management
- Images
- Complement Depletion and Disease Models
- Human C3-1496 Potential Immunogenicity
- C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
- sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
- sC3 Depletes Complement More Potently than CVF
- sC3 is More Stable in Serum
- sC3 Resists Degradation
- sC3 Gene Therapy Strategy
- sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
- sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
- sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
- sC3 Cascade Intellectual Property
- Gallery
- What's Hot in Complement 2020-2021
